1. Scrip
  2. >>COVID-19

Bill Gates On Vaccine Distribution Challenges, Overcoming Vaccine Hesitancy

 
• By Jessica Merrill

The public health advocate and billionaire philanthropist raised issues about how a mass COVID-19 vaccination effort is being handled so far in the US, speaking at the Stat Summit.

PARIS, FRANCE - APRIL 16: Co-chairman and co-founder of the The Bill and Melinda Gates Foundation, Bill Gates speaks to the media after his meeting with French president Emmanuel Macron.
Bill Gates addressed the Stat Summit • Source: Shutterstock

Billionaire philanthropist and public health advocate Bill Gates is concerned about US preparedness to end the COVID-19 crisis. The infrastructure for mass vaccination in the US is not coming together in a "rational fashion," he warned during a session at the Stat Summit on 17 November, as states have been given too little direction amidst a lack of federal leadership.

"It is so cacophonous. It could work out in a decent way,” Gates said, but, he added, “It doesn't appear...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

 
• By Kevin Grogan

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

 
• By Kevin Grogan

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

More from Scrip

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 
• By Andrew McConaghie

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By Manas Mishra

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.